<SEC-DOCUMENT>0001144204-13-005918.txt : 20130205
<SEC-HEADER>0001144204-13-005918.hdr.sgml : 20130205
<ACCEPTANCE-DATETIME>20130204194942
ACCESSION NUMBER:		0001144204-13-005918
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130204
FILED AS OF DATE:		20130205
DATE AS OF CHANGE:		20130204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		13571681

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v333899_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 0.5pt; border-top: Black 0.5pt solid; border-bottom: Black 0.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of February, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <B>000-51310</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9;<B>XTL Biopharmaceuticals Ltd.&#9;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>85 Medinat Hayehudim St., Herzliya </B><BR>
<B>Pituach, PO Box 4033,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>_________Herzliya 46140, Israel_________</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F&#9;</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9;Form 40-F</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9;No </FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-<U> N/A </U>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 0.5pt; border-top: Black 0.5pt solid; border-bottom: Black 0.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. dated February 4, 2013 is hereby incorporated by reference into the registration statements
on Form F-3 (File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on March 23, 2007, October 30, 2007 and August 15, 2008, respectively, and the registration statements
on Form S-8 (File No. 333-148085, File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on December 14, 2007, January 18, 2008, and October 28, 2008, respectively.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>XTL Biopharmaceuticals &ndash; Immediate
Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">To
the holders of American Depositary Receipts (&ldquo;ADR&rsquo;s&rdquo;) representing common shares of XTL Biopharmaceuticals, Ltd.
(the &ldquo;Company&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">Following
requests of shareholders and warrant holders of the Company in the past few days to extend the duration of our (tradable) warrants
(series 2) from February 27, 2013 to December 31, 2013, we approached the court in Israel with such request. The court permitted
us to convene two extraordinary meetings for this resolution (a shareholder meeting and a warrant holder meeting). Today, we announced
that both meetings will take place on February 21, 2013. Due to the quick timing of these extraordinary meetings, we will not be
able to follow our normal procedures soliciting the vote of the ADR holders at the extraordinary meetings and as a result you will
not be able to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">Below&nbsp;is
a summary English translation (from Hebrew) of an immediate report by XTL Biopharmaceuticals Ltd. as published today on the Tel-Aviv
Stock Exchange Ltd.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_006.jpg" ALT="" STYLE="height: 59px; width: 139px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&#9;</FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt">Tel-Aviv-Jaffa District Court</TD>
    <TD STYLE="padding: 0; text-align: center">Liquidations 55947-01-13</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; padding: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">On the matter of:</FONT></TD>
    <TD STYLE="width: 78%; padding: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">XTL Biopharmaceuticals Ltd. Public Company Nr. 520039470 (hereinafter:
        The Company)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">through Victor Tshuva, Adv. of 3 Hayetzira St., Ramat Gan 52521,
        Israel</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel: +972 3 613 8484; Fax: +972 3 613 8585</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Convening Notice of General Meetings
of Company Shareholders</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>and Holders of Company Warrants (Series
2)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the resolution of the
Tel-Aviv Jaffa District Court in Israel dated January 30, 2013 on Liquidations 55947-01-13, instructing that an extraordinary general
meeting of Company shareholders and warrant (series 2) holders (Hereinafter: &quot;<B>Warrantholders</B>&quot;), be convened for
the purpose of extending the exercise period for the warrants (series 2) to December 31, 2013, we hereby give notice of convening
general meetings as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The general meetings will be held on <U>Thursday
February 21, 2013</U> at the Law Offices of Victor Tshuva, 3 Hayetzira St. (S.A.P. Building, 7<SUP>th</SUP> floor), Ramat-Gan,
Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General meeting of shareholders shall be
held at 11:00 a.m. Israel time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General meeting of Warrantholders shall
be held at 12:00 p.m. Israel time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>The subjects on the agenda for these
meetings</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Extending the exercise period for the Company
warrants (series 2) until December 31, 2013 in accordance with the provisions of Article 350 of the Israeli Companies Law, 1999
(Hereinafter: <B>The Settlement</B>), according to the version submitted to the court which is available at the offices of the
undersigned or on the website of the Tel-Aviv Stock Exchange (www.tase.co.il) or from the distribution website (www.magna.isa.gov.il);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>A summary of the proposed resolutions</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To approve the extension of the exercise
period for the Company warrants (series 2) to December 31, 2013;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>The majority required for passing the
resolution</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to pass the proposed resolution
at the general meetings of the Company&rsquo;s shareholders and Warrantholders, a vote of the majority of participants who jointly
hold 75% of the votes of those present and voting at the meetings, or their proxies, is required. At such meetings, shareholders
and Warrantholders will be required to declare their cross-holdings in Company shares and warrants (series 2) and to the extent
necessary, the resolutions passed during the shareholders and/or Warrantholders meetings shall be examined for their purity;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Articles of Association
of the Company, the legal quorum for holding a general meeting is the presence, in person or by proxy, of at least two shareholders
holding at least 33.33% of the voting rights, within half an hour from the time set for opening the meeting. Should a legal quorum
not be present, the meeting shall stand adjourned to the same day in the next week at the same time and place (hereinafter: <B>The
Deferred Meeting</B>). Should a legal quorum not be present at the Deferred Meeting a meeting shall be held with whatever number
of participants are present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>The record date</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with Article 182(c) of the
Israeli Companies Law, Regulation 3 of the Israeli Companies Regulations (written voting and statement of position) 2005, the record
date with regard to a shareholder's right to participate and vote at the meeting is Thursday, January 24, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Voting by a proxy card will be valid on
condition that it is received at the Company's official address with a proof of ownership, no later than 72 hours prior to the
time scheduled for convening the meeting (<I>i.e.</I>, until 12 p.m. (Israel time) on Monday, February 18, 2013). The voting shall
be done on the second part of the proxy card. Each shareholder and/or Warrantholder shall be required to declare on the proxy
card any cross-ownership (to the extent there is any) in shares and/or warrants (series 2). Additionally, the dates for submitting
objections were published within the request for settlement submitted by the Company and published through the Magna website (<FONT STYLE="color: Blue"><U>www.magna.isa.gov.il</U></FONT>)
and the Maya website (<FONT STYLE="color: Blue"><U>http://maya.tase.co.il</U></FONT>) on January 29, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The last date for presenting position statements
by Company shareholders is February 7, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The last date for presenting the Board
of Directors' response to the position statements is February 12, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of the complete version of the
Settlement, including additional information regarding the meetings and the form of proxy have been published as part of the Company's
immediate reports dated February 3, 2013 through the Israel Securities Authority internet website <FONT STYLE="color: Blue"><U>www.magna.isa.gov.il
</U></FONT>and the Tel-Aviv Stock Exchange website <FONT STYLE="color: Blue"><U>maya.tase.co.il</U></FONT>. Additionally, one
can receive a copy of the Settlement from the Law Offices of Victor Teshuva &amp; Associates as of January 29, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5in; text-align: justify">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5in; text-align: justify">XTL Biopharmaceuticals Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Proxy Card &ndash; Part One</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with Regulation 7 of the Israeli Companies Regulations
(written voting and position statements), 2005 (hereinafter: <B>The Regulations</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; border: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Company Name </FONT></TD>
    <TD STYLE="width: 75%; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt; font-weight: bold"><FONT STYLE="font-size: 10pt"><B>XTL Biopharmaceuticals Ltd. (The Company)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Type of meeting</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">An extraordinary general meeting of Company shareholder and holders of Company warrants (series 2) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Time and place of meeting:</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">The meetings shall be held at the law offices of Adv. Victor Tshuva &amp; Associates, of 3 Hayetzira St. S.A.P. Building 7<SUP>th</SUP> floor, Ramat Gan, Israel on Thursday 21.02.2013 at 11:00 a.m. and 12:00 p.m. Israel time</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Subjects on the agenda: </FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Extension of the exercise period of the Company's warrants (series 2) until December 31, 2013 in accordance with Article 350 of the Israeli Companies Law 1999 (hereinafter: <B>The Settlement</B>), in accordance with the version submitted to court which can be received at the Law Offices of Adv. Victor Tshuva &amp; Associates as of January 29, 2013 or from the TASE internet website www.tase.co.il or the distribution website www.magna.isa.gov.il </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">The version of each of the proposed resolutions:</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">To approve the extension of the exercise period of the Company warrants (series 2) until December 31, 2013.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Location and time for reviewing the complete version of the proposed resolutions: </FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">The complete version of the request for settlement between the Company and its shareholders and between the Company and its warrant (series 2) holders (Hereinafter: <B>&quot;Warrantholders&quot;</B>) and the immediate report with regard to convening a general meeting can be reviewed at the Law Offices of Adv. Victor Tshuva, at 3 Hayetzira St., Ramat-Gan, Israel (Tel: +972 3613 8484) by pre-coordination with Adv. Victor Tshuva (Sun to Thur. 11 a.m. to 3 p.m. Israel time) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">The required majority to pass a resolution at the meetings for each of the subjects on the agenda: </FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Passing one of the proposed resolutions at the general meetings of Company shareholders and Warrantholders requires that a majority of participants who jointly hold 75% of the votes of those present and voting at the meetings, or their proxies. Within the framework of the Company's shareholder and Warrantholder meetings, the shareholders and Warrantholders will be required to declare their cross-holdings in Company shares and warrants (series 2) and to the extent necessary, the resolutions passed at the shareholder and/or Warrantholder meetings shall be examined for their purity.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Providing details regarding an affinity:</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Within the framework of the Company's shareholder and Warrantholder meeting, the shareholders and Warrantholders will be required to declare their cross-holdings in Company shares and warrants (series 2) and to the extent necessary, the resolutions passed within the shareholders and/or Warrantholders meetings, shall be examined for their purity.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt; width: 25%; border-top: Black 1pt solid"><FONT STYLE="font-size: 10pt">Validity of the proxy card:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 75%; border-top: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The proxy card will be valid only with an attached proof of
        ownership of the shareholder/Warrantholder who is not registered, or a photocopy of an ID card, passport or Certificate of Incorporation,
        if another shareholder/Warrantholder is registered in the Company Books.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, the proxy card must be presented no later than
        72 hours prior to the time of vote.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Address for submitting proxy cards and position statements:</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">The address for submitting proxy cards is the Law Offices of Adv. Victor Tshuva, at 3 Hayetzira St. (S.A.P. Building &ndash; 7<SUP>th</SUP> Floor) Ramat-Gan, Israel Tel: +972-3 613 8484, Fax: +972 3613 8585</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">The last date for submitting position statements to the Company and the last date for submitting the Board of Directors' response to the Position statements:</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The last date for submitting position statements is February
        7, 2013.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The last date for submitting the Board of Directors' response
        to the position statements is February 12, 2013.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">The addresses of the distribution website and internet website of the TASE where the proxy cards and position statements are available</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A
    copy of the proxy card can be downloaded from the TASE website (<FONT STYLE="color: Blue"><U>www.tase.co.il</U></FONT>) or
    from the distribution website (<FONT STYLE="color: Blue"><U>www.magna/isa.gov.il</U></FONT>). Additionally, a shareholder
    or Warrantholder is entitled to approach the Company directly (through Adv. Victor Tshuva) and receive from him the proxy
    card form.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Receipt of a proof of ownership:</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A shareholder is entitled to receive the proof of ownership at the branch of the member of Stock Exchange or by post, if so requested, whereas, such a request shall be given in advance to a specific securities account. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Link to the proxy card form:</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A non-registered shareholder in entitled to receive free of charge by email a link to the proxy card form and position statements on the distribution website from the member of the stock exchange through whom his stock is held, unless he notified the Company and/or the Stock Exchange that he is not interested in receiving a link as aforementioned, and that he is interested in receiving the proxy card by post in return for payment; a shareholder's notice with regard to proxy cards shall apply also to the receipt of position statements. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Reviewing the proxy cards;</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">One or more shareholders holding shares at a rate that constitutes five percent or more of the total voting rights in the Company, and also anyone holding an aforementioned rate from the total voting rights that are not held by a controlling shareholder in the Company in accordance with its definition in Article 268 of the Israeli Companies Law, 1999, is entitled to review the proxy cards after the convening of the general meeting at the Company's registered offices during the regular working hours, after he has proven his right to do so, and has also stated the number of shares which constitute the aforementioned five percent.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: windowtext 1pt solid; padding-top: 6pt; padding-bottom: 6pt; width: 25%; border-top: Black 1pt solid"><FONT STYLE="font-size: 10pt">The vote: </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; width: 75%; border-top: Black 1pt solid"><FONT STYLE="font-size: 10pt">A shareholder shall state his vote regarding each of the subjects on the agenda on a form that constitutes the second part of the proxy card. The proxy cards shall be submitted to the Company offices no later than on Monday, February 18, 2013 until 12:00 p.m. (noon) Israel time.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Proxy Card &ndash;Part Two</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with Regulation 5(a) of the Israeli Companies
Regulations (voting in writing and position statements) 2005 (hereinafter: The Regulations)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; padding: 0"><FONT STYLE="font-size: 10pt">Company name</FONT></TD>
    <TD STYLE="width: 56%; padding: 0; font-weight: bold"><FONT STYLE="font-size: 10pt"><B>XTL Biopharmaceuticals Ltd.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 10pt">Company address (for submitting and sending proxy cards)</FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 10pt">of 85 Medinat Hayehudim St. Hetzelia Pituach 46766</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 10pt">Company number</FONT></TD>
    <TD STYLE="padding: 0; font-weight: bold"><FONT STYLE="font-size: 10pt"><B>520039470</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 10pt">Date &amp; time of meeting</FONT></TD>
    <TD STYLE="padding: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thursday &ndash; February 21, 2013</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At 11:00 a.m. and at 12:00 p.m. - noon Israel time</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 10pt">Type of meeting</FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 10pt">An extraordinary general meeting of Company Shareholders and general meeting of Company Warrantholders</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 10pt">Record date:</FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 10pt">January 24, 2013 at the end of trading day. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Details of the shareholder/Warrantholder</FONT></TD>
    <TD STYLE="width: 56%; border-bottom: windowtext 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><I>&nbsp;</I></TD>
    <TD STYLE="padding: 0 0 1pt"><I>&nbsp;</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Name of the shareholder/Warrantholder</FONT></TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">I.D. number</FONT></TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Passport number (if does not have an Israeli I.D.) </FONT></TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Country issued</FONT></TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Valid until</FONT></TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Corporation Number (if the shareholder is a corporation)</FONT></TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Country of incorporation</FONT></TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">The vote</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; font-weight: bold">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD ROWSPAN="2" STYLE="border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Subject on the agenda</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">The Vote<SUP>1</SUP></FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Existence of personal interest</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">For </FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Against</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Abstain</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41%; border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Extend the exercise period of the Company's warrants (series 2) until December 31, 2013 in accordance with the provisions of Article 350 of the Israeli Companies Law, 1999 </FONT></TD>
    <TD STYLE="width: 11%; border-bottom: windowtext 1pt solid; border-right: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 11%; border-bottom: windowtext 1pt solid; border-right: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 13%; border-bottom: windowtext 1pt solid; border-right: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 13%; border-bottom: windowtext 1pt solid; border-right: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 11%; border-bottom: windowtext 1pt solid; border-right: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Cross-holding<SUP>2</SUP></FONT></TD>
    <TD STYLE="width: 50%; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Detail the number of shares/warrants (series 2) held by the shareholder / Warrantholder with a proof of ownership attached</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">*I hold / do not hold also Company shares / warrants (series 2) </FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Date</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Signature</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> No markings shall be considered abstention from
voting on that subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2</SUP> To the extent that the shareholder wishes to participate
in the shareholders general meeting he must declare whether he also holds warrants (series 2) and the number of warrants (series
2) held by him. To the extent that the Warrantholder wishes to participate in the shareholders general meeting he must declare
whether he also holds shares and the number of shares that are held by him, including attaching a reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*Erase the irrelevant&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About XTL Biopharmaceuticals Ltd. (&ldquo;XTL&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">XTL
Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical
products for the treatment of clinical unmet needs. XTL is focused on late stage clinical development of drugs for the treatment
of multiple myeloma, schizophrenia, and hepatitis C. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">XTL&rsquo;s
lead drug candidate, rHuEPO, for the treatment of multiple myeloma blood cancer, was granted an orphan drug designation from the
FDA. rHuEPO has been approved for marketing by the FDA and has for many years been sold for billions of dollars across the world
for the treatment of severe anemia. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">XTL
holds the controlling stake in Proteologics Ltd. (TASE: PRTL), a drug discovery company, and InterCure Ltd. (TASE: INCR), a company
which has disrupted the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device,
RESPeRATE&reg; (www.resperate.com).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">XTL
is a public company traded on the Tel Aviv Stock Exchange (TASE: XTL) and its ADRs are quoted in the US on the Pink Sheets (OTC:
XTLBY). XTL shares are included in the following indices: Tel-Aviv MidCap-50, Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Bluetech-50.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations, XTL Biopharmaceuticals
Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +972 9 955 7080, Email: <FONT STYLE="color: Blue"><U>ir@xtlbio.com,
www.xtlbio.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U></U></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cautionary Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of the statements included in this
Form 6-K may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><B><B>XTL BIOPHARMACEUTICALS
LTD.</B></B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">Date: February 4, 2013</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%">/s/ David
Grossman</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Name:&#9;David
Grossman<BR>Title:&#9;Chief
Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`"T`@8#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBBD`44
M44P"H+J[BM(C)(P`%3,P123TKR+XD>+6LE>&-\?C6E.FYRLB)SY5<W=:^)=K
MI[M'&4R*P[?XN(9L,ZD9[UX3>7L]_.9'<\GUJ`QLHR&.:]..#C;4XY5Y7/K7
M1/&%IJZKM903Z&ND!#`$'(KY(\,>)KC3+R-3(<9]:^EO">LC4]-1RV3BN+$4
M/9O0Z*57FT9T5%%%<IN%&:*,4`&:,TE&*`%HHHH`****`"BBB@`HHYHH`***
M.:`"BBB@`S1110`49I,44`+12"EH`****`"C-%)0`N:*3%&*`%HHHH`****`
M"BBB@`HHHH`***2@!<T9I*,4`+124M`!1110`4444`%%%%`!1110`4444`%%
M%%`$;S(A^9@*;]J@_P">J_G7.>+);BWM))8<\#M7AU_X_P!0L[YHV=P`:WIT
M74V,9U>1GTK]IA_YZK^='VF#./-7\Z^:A\2;P_\`+1OSJ-OB1?!\^8U:_4YD
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M(UU)V/:_,7&2P`IGVF#./-7\ZY+Q1JDNF:87!(.VO%9_B1>K>.HD;`/K4T\/
M*>Q4ZRB?2_VF'_GJOYT?:8?^>J_G7S5_PLB]_P">C?G1_P`+(O?^>C?G6GU.
M9'UE'TK]IA_YZK^='VF'_GJOYU\U?\+(O?\`GHWYT?\`"R+W_GHWYT?4YA]9
M1]*_:8?^>J_G1]IA_P">J_G7S5_PLB]_YZ-^='_"R+W_`)Z-^='U.8OK*/I7
M[3#_`,]5_.C[3#_SU7\Z^:O^%D7O_/1OSH_X61>_\]&_.CZG,/K*/I7[3#_S
MU7\Z/M,/_/5?SKYJ_P"%D7O_`#T;\Z/^%D7O_/1OSH^IS']91]*_:8/^>J_G
M1]IA_P">J_G7S5_PLB]_YZ-1_P`+(O?^>C?G1]3F+ZRCZ5^TP?\`/5?SH^TP
M?\]5_.OFK_A9%[_ST;\ZCD^)-Z%_UC?G1]3F'UE'TTL\3?==3]#3^M>)>!O&
M=SJETJ2.3S7M,#;H58]Q7/4IN#LS:%13):***R-`HHHI@(:*6D/2@!#(J]6`
MIOVB+_GHOYUR7B;5I+)&*DBO/_\`A,KK[01O.,UVT<%.K'F1YU?,(49<K/;Q
M(C=&!IU<-X7UJ6^9=Q)KN1TKFJ4W3ERLZZ%958\R"BBBLS8****`"BDI:`"D
MZ=:7O4%VYCMV8=A32NQ-V5QYFC'5P*//B/\`&OYUY5X@\43VMTR*QZUFV?B^
MY>Y52YP37?'+YRCS'ERS2G&?*>U!@>AS2UCZ%=M=6JNQZBMBN&<>65CTJ<U.
M/,@HHHJ2PHHHH`**,T4`%%)2T`%%%%`!1110!5O[1+RU>)@#D5\]?$7P@UG.
M\\:=\]*^C^]<SXNT--5L'^7)Q6^'J\DC*K#F1\DQH5)#=:D,>5K:\4:0^EZ@
MZ[2!FLE&RHKVXR4E<\V=TRUH6H2:7?I(&P,U]%>&+BV\2Z0(Y<,VVOF>92,$
M5Z/\.?%#V%RD#/@$XKFQ5+F7,MS:C/74Z/Q/\+@]TTL2<'G@5S4'PSFDFVE#
MC/I7T1:2QW]FDA`8$4];*!&R$&:X%BIQ5CI]A%ZG`^%?`-OH]N)I4&0,\URO
MQ&\4+`CV<+8`XP*]%\9:^ND6#JK`';7S+XBU-]4U%Y"Q(S6V&A*K+FD9U9**
MY491WS3L['.3FG%=HJ11M4&F$--(J*,DFO3=D<=VV6-)TR74=02-5R":^E/`
M?A9-,L8Y60`D"N&^&WA+S=EQ(GOR*]P@B$,"1@<**\O%UKOE1W4*?VF<#\26
M']G.!Q@5\T7&/MLG/>OIKQ_9275BZH">#7SW/X7O3>.0C8SZ5K@Y)1U(K)N1
ME8'K1A?6M?\`X1>]_N-^5'_"+WO]QORKM]I$YN1F1@>M&W/2MC_A%KTC.QOR
MJM/I<UG_`*Q2*%--V$XM(H[#1L-2$\XHSBK(NR/9BDP/6K,4#7!VH,FKR>&+
MR1=P1L?2I<DMRHILR./6C`]:U_\`A%[W^XWY4?\`"+WO]QORI>TB5RLR./6E
MVYZ5K'PM>@9V-^55)]/ELS^\!'UIJ<7HA.+14V&HY$.TU8S4<GW356)3=SOO
MA@A%^I]Z^D[7_CW3Z5\X?#'_`(_E^M?1]K_Q[I]*\?&?&=^&V)J***XSJ"BB
MB@`H/0T4'H:`///&HS&U>4;?])/UKUGQG_JVKRC_`)>3]:^FRW^$?(YG_&/2
M?!`PZUZ>.@KS'P3]]*]-'05XN._BL][+?X*%HHHKC/0"BBDH`6DHI:`"JU__
M`,>;_2K'>HYT\R)E]::W%)75CP?Q6DG]HM@'&:Q[&.7[9'\IZUZ_J?A07<Q?
M;FJD'@Q8Y0VSI7O4\?!4^5GS-3+JKJ-HW_"H(L$SZ5T54--M/LD(3&,"K]>)
M5ES3;1]#0BX4U%A11161L!I**6F`E%%%`!2TE%`"T444`%%%%`"4,H92IZ&E
MI*`/(?B/X3$\<EPB>_2O")8WM[EHV&,&OL?5K!-0L7B90217S=X]\,OIMX\B
MI@9]*]/!UK^ZSBKT[:G&$!A3K"Y>SOTD!P`:AB;"X-$B_+D=:]&5FCCCHSZ4
M^'_B5;ZTC@+Y/'>NZOKD6EH\Q.-HKYI^'>O-I]ZN]L`'O7J7BGQK#+I!2-QD
MKV->/6H/VFAWTZONZGGOQ&\4&]N'A1_;K7FT0+9)ZU8U&X>[U"1V)()J/A!7
MITH<D;''4E<1VP-O>NG\%>'Y-3U!"R$KGTKGM/LY+Z^1%4D$U]&>`?"Z6-G'
M.R8.!VK+$UE")=&GS,ZS0-)CTNP1%4`XK6)I<8&!28KQF[NYZ25M"I=V$=XA
M5P#FL<^$+,N6V+GZ5TE%"DUL#BF<Y_PB-G_<7\J/^$1L_P"XOY5T=%5[27<7
M)$YT>$K,`C8OY5Y3\0='ALM^Q0,5[QVKQ;XG,29*WP\I.>YC6BE$\2)_?D>]
M),<`4'_7M]:)NE>TMCSG\1T_@ZU6ZO45AGFOH/3/"MHUA&S(N2/2O`O`QQJ$
M?UKZ<T@DZ;%GTKRL9)J6AW8>*:,K_A$;/^XOY4?\(C9_W%_*NCHKC]I+N=/)
M$YT^$K,J1L7\J\:^)>DQ:>[>6H%?0S'"$^U>#?%=BTCYKHPLFYG/7BE$\BC.
M11)]VDCI9/NU[1P=3T+X8_\`'\OUKZ/M?^/=/I7SA\,?^/Y?K7T?:_\`'NGT
MKQL9\9WX;8FHHHKC.H****`"@]#12'H:`//_`!G_`*MJ\H_Y>3]:]7\:?ZIJ
M\H_Y>3]:^ERW^$?(YG_&/2_!/WTKTT=!7FG@E1N4DUV6K:[#IT1)89Q7D8N+
MG6LCV\#.,,/>1K/*D?WF`J(WUN/^6@KS#5/&^]R$?]:PG\57#'AS^=7#+:DE
MJ14S:G%V1[:+V`])!4BR(_W6!KQ*+Q9,AY<_G6YIWC?8P#O^M$\NJ15T$,VI
M2>IZIBDK"TOQ'!?*!N&36ZK!AD'(K@E"47:1Z5.I&HKQ8&BBF3-LB9O2I+>F
MH_<OJ*-R^HK@M8\6BQG*;NAJC:^.!-.$W=:ZHX.I*/-8X99A2C+E/2\CM15#
M3+K[7;A_45?KF:<79G;"2FKH6BBH+F[CMHRSL!22;V&VDKLGZ5$UQ$GWG`KD
M-5\9Q0;E5A7(WGC1Y&.U_P!:[*6!JSUL<%7,:5-VN>M&^MQ_RT%`O;<])!7B
M3^*[@MPY_.I(O%DZGES^==']ESL<W]L0OL>W+*C_`'6!I]>4:?XW*,-[UV>F
M>*8+P*"PR:Y:N$J4]T=E''TJNESI**;'(LBAE.0:=7*=H4444`%%%%`!7#^.
MO#BZG:.ZH"<9KN*CFB6:)D89!&*J$G%W1,H\RL?'.M:>^G7[QD$`&JHPRXKU
M[XD>$]C/<1Q^_2O'@&CE*L,8->W1J*<3S*D;,G@F>U;<AP:L2ZM<3KM9R153
MK0`*V<4978;>2QJ-@9F"+UISMV%=)X.T"74M10LA*YJ9R48ZE0BVSLOAMX2-
MPZ3RI[\U[S:VZVUNL2C``K*\/:-'I=D@50#MK;KQ*U1SD>G2ARH****Q-0HH
MHH`****``]*\5^)OWGKVH]*\5^)OWGKIPOQF-?X3Q)O]>WUHGZ4-_KV^M$_2
MO;6QYOVCK/`W_(0C^M?3FC_\@V+Z5\Q^!O\`D(1_6OIS1_\`D&Q?2O)QNYW8
M<O4M)2UPG4-?[C?2O!OBK_K'KWE_N-]*\&^*O^L>NK"?&<^(^$\CCHD^[1'1
M)]VO:/.ZGH7PQ_X_E^M?1]K_`,>Z?2OG#X8_\?R_6OH^U_X]T^E>/C/C._#;
M$U%%%<9U!1110`4AZ&B@]*`//_&?^K:O*@/])S[UZKXT_P!4U>5_\MF^M?2Y
M9_#/D<TTK'8:3K"V$.0<'%9&NZ[-J$FQ6-9#R.V%4FNH\-^&GOW5W7(K2<*=
M%NI(QIU*M9*G$YRWT>ZN?F"GFKP\,WF,[3^5>P:?X;@MHU#(*U!IEL!C8*X)
MYJ[^ZCTX9.VKR9X'/H-W%R5-4&A>%L-D$5]`W6AV\R$!!7"^)/"/E(TB+6^'
MS)3?+(Y\3E<Z<;Q.*TS6I[*9<,<`UZQX9\1)>Q*C-S7C,\#0.RL,$5J^'=3D
ML[M<MQFM\9A(58<T=S#!8N=&I9['OH((R*AN_P#CUD^E4]%OA>6BMG)Q5V[_
M`./9_I7S3BXRLSZSF4X71X=XN0F_;GO6+IJ'[='SWK=\7?\`'\WUK%TS_C^3
MZU]51_@'QE7^._4]R\-#&GI]*W*Q/#?_`!X+]*V)9!%&7/:OEZW\1GU^&TI(
MKWU]'90EW('%>6>)?%CR2LD3G'M5[QGKY.Z.-J\X9WF<LQR37KX#!*W/,\3,
M<>V_9P'SW,MT^68G-36VD7-R?D4XK:\/^'WU"525XKU#2O#,-K&NY!FNG$XV
M%'W8G)A<!4Q'O/8\IC\)W;KG:?RJ.?PO=Q`G:?RKW9+*W08$:U'-IUO,I!C%
M<"S6=]4>B\FC;1GSO/92VS?."*GL]5GLY%*L<`UZIKWA%)86D1>:\NU+37L9
MF5EQ@UZ>'Q-/$*S/*Q&%J8:5STOPMXI$X6.1^?>N\CD65`RG(-?.>GWDEG<*
MZL0,U[%X3UL7D"JS9.*\O,,'[-\\=CV,MQWM%R3W.MHHHKRCV@HHHH`****`
M,7Q'I<>HZ>ZL!G%?,_C'2!IE\^T8YKZ5\3:O%ING.S,,XKYG\7:P-4OGV^M>
MA@N:_D<6)L<]&<K3STIL8PM.KU3A>XV$;KI%/0FOH7X;:3;"TCEPN[%?//W)
M`X[5ZK\.O%WE3QV[O@9QUKDQ<6X:'11:YCZ!`P,"DJ*VG2X@21#D$9J7O7BG
MIBT444`%%%%`!1110`'I7BOQ-^\]>U'I7BOQ-^\]=.%^,QK_``GB3?Z]OK1/
MTH;_`%[?6B?I7MK8\W[1UG@;_D(1_6OIS1_^0;%]*^8_`W_(0C^M?3FC_P#(
M-B^E>3C=SNPY>I:2EKA.H:_W&^E>#?%7_6/7O+_<;Z5X-\5?]8]=6$^,Y\1\
M)Y''1)]VB.B3[M>T>=U/0OAC_P`?R_6OH^U_X]T^E?.'PQ_X_D^M?1]M_P`>
MZ?2O'QGQG?AMB:BBBN,Z@HHHH`*0]#2TAZ&@#S_QI_JVKRIO]8WUKU7QI_JV
MKRES^];ZU]-EO\,^0S3^,:&D6OVN[5<9YKVKPYIRVEHIV\XKS#P=;>9>J2.]
M>SVT8C@4#TKAS2JW+E/0R>BK<[):,TE%>.>^+FJU[;+=6[(P!XJQ2T)V=Q22
MDK,\3\7:7]EN&*C'-<JCF-U(]:]1\<VP;<0*\MF&)<>]?58&?M*6I\;CJ7LZ
MSL>M>"-0W0*A/:NWN>;5S[5Y3X,G*R(N:]4D.;%C_L5X6-I\E8^@R^HYT-3Q
M/Q=_Q_M]:Q=,_P"/Y/K6UXN_X_V^M8VF?\?R?6OH*/\``/FZW\=^I[EX;'_$
MO7Z5)K]V+>P?G!Q3?#?_`"#5^E8/C.[*1,N:^=4.>O8^H<^3"W/+M8NFN;Y\
MGC-,TJT-S=JF,C-59VW7+'U-==X1L0]TCD=Z^CJS5*CH?+4HNK6L>B>&M(2S
MME;:,XKHZBMT$<"*/2I*^4J3<Y-L^SHTU3@HH,T9I:2H-1&4.I4\@UY[XTT-
M2K2(OO7H8K*URV$]HV1GBM\/5=.::.7&455I-,^?[B(Q.5/8UU?A#46MYU3=
MWK&UZ#R;YACO4>D3&*]3![U]/52JT3Y*E)TJQ]`V<GFVJ/ZBBJ6@2^;ID9]*
M*^3FK2:/M*<N:"9IT445)8M0W,ZV]N\C'``J4D`9->=_$+Q2FGVKQ1OSBKIP
M<I61,Y<JN<'\1?%K2S/;H^1G'6O*5S)(6;O5C4KQ]0O&E9B<FHONIFO<HTU"
M-CRZD[L#Q2!JM:?9O?R[$!)K2O/#=S:1>8R$#Z5;FD[,A19BD94U)IMX^G7B
MRJ2,&HLX<KW%-E7(XJI)-!%V9](_#WQ.NH6J1R/SC'6O1`<C(KY1\&>(7TJ_
MC0N0,U],:!JD>HZ=&X8%L5XN)I<DKH]&A4YE9FO24M)7*=`4444`+1110`'I
M7BOQ-^\]>U'I7BOQ-^\]=.%^,QK_``GB3?Z]OK1/TH;_`%[?6B?I7MK8\W[1
MUG@;_D(1_6OIS1_^0;%]*^8_`W_(0C^M?3FC_P#(-B^E>3C=SNPY>I:2EKA.
MH:_W&^E>#?%7_6/7O+_<;Z5X-\5?]8]=6$^,Y\1\)Y%'2R?=I(Z63[M>T>=U
M/0OAC_Q_I]:^D+;_`(]T^E?-_P`,?^/]/K7TA;?\>Z?2O'QGQG?AMB6DI:*X
MSJ$HI:*`$I3T-%!Z&@#S[QG_`*MJ\I;_`%Q^M>K>-/\`5-7E)_X^#]:^ERW^
M$?(YG_&.\\$1_P"D*?>O6EX4?2O+?!('FK7J0Z"O(Q[O5/;RM6HBT445PGIA
M1110!Q/C-08FKR"YXN3]:]@\9?ZIJ\>NO^/EOK7T>5_`?*YK_%.O\('_`$E/
MK7KS?\@\_P"Y7D/@\?Z2GUKUYO\`D'G_`'*\_,OXIZ65?P6>*>+O^/\`;ZUC
M:9_Q_)]:V?%W_'^WUK%TS_C^3ZU[5'^`>!6_COU/=?#?_(,7Z5Q_CJ3#,*[#
MPW_R#%^E<7X[4[VKP\/_`+R?0XI_[(CS1CF?\:])\%Q@E#7FK?Z[\:],\%,,
M+7KX_P#@GBY<KUD>EI]P?2G4B_<'TH[U\N?8"T444`%5[U=UJX]JL5#='%M)
M]*<=R9?"SP[Q4FW4&^M8UD<7J?6MSQ80=0;ZUAV7_'XGUKZVC_!1\16_COU/
M<O"A)TL44GA/_D%BBOEJ_P#$9]CA?X2-\T@I:BGG2WB+N<`"LMSH,OQ%JL>F
MZ<[E@&Q7S1XP\0R:K?2)O)&?6NV^)/BXO*]O&_'3@UY$,R2F1N237JX2C9<S
M."O4N["Q+@<TC$L=@ZFGN=HJ]H6F2:AJ,8"DC-=TY65SFBKL[OX9^'&N+I9)
M4RI/<5ZIXI\+P2:.YCC&Y5]*N>#-"CT[3HWV@-BNFN(1/`\9&017BU:[E.YZ
M,*2Y;'QUK-C)8:E(&4@9JJC!Q7J_Q,\+>2[S1I[\"O)%!B8HW6O5HU%.-SAJ
M0L["@M#.)%[5[%\-O%I+I;R2<=.M>0,-RU:T;4'TN]216(YHKTE.(4IN+/L:
M*59HE=3D$4^N)\">)$U+3U1W!;`[UVW49KPYQ<79GIQES*X4HI*45)04444`
M!Z5XK\3?O/7M1Z5XK\3?O/73A?C,:_PGB3?Z]OK1/TH;_7M]:)^E>VMCS?M'
M6>!O^0A']:^G-'_Y!L7TKYC\#?\`(0C^M?3FC_\`(-B^E>3C=SNPY>I:2EKA
M.H:_W&^E>#?%7_6/7O+_`'&^E>#?%7_6/75A/C.?$?">11TLGW:$I9!E:]H\
M[J>@_#$$WRX]:^D+8$6Z9]*^;/AK=QVMZID('/>OH&+Q!9&)?W@Z>M>1C$W,
M[L,U8UZ3%9?_``D%C_ST'YT?\)!8_P#/0?G7)RLZN9&IBC%9?_"0V/\`ST'Y
MT?\`"0V/_/0?G1RL7,C4Q2GI65_PD%C_`,]!^='_``D%CC_6#\Z.5CYD<IXT
M4^6_%>3MQ.?K7J'BW5;>YB8(P->8.O[QC[U])EJ?LSY+,VO;'?\`@B4>>HS7
MJZ\J/I7A_A&^$%ZH)[U[39SK/;JP.>*\K,J?+4N>OE%3FIV+%%%%><>N%%)3
M99!%&6)Z"@5S@_&]P%5AFO)YSNG)]Z[CQOJ`EG95-<.%,DB^YKZC+X<E*[/C
M\PJ<]=G=^"[<M(C8KU208L6'^S7%>!['$"N1VKM[KBU<>U>+C:G-6/>R^GR4
M#Q'Q=_Q_M]:Q=,_X_D^M;7B[_C_;ZUBZ9_Q_)]:]^C_`/FJO\=^I[KX;_P"0
M:OTKF/&UN65FQ73>&_\`D'+]*K>*++SK)V`[5\]"?+B+GT]2'/A;'ADHQ.1Z
M&NZ\&W869%S7&7T1BO'!'>M#P_?&VOE)/&:^@Q$?:43YG#5/9UD>^1',2GVI
M]9VCWJW=HA!R0*T:^4E%IV/M824HIH****10@JEJLPBLWR>U7JY+Q?JBV]NR
MANU:48.<TD88BHH4VV>7>))O,U!L'O5#3HR]ZF/6H[^<SW#/[UK^&K,W%VAQ
MWKZI_NZ.I\<E[6L>P^&HO+TM/>BKNF1>381K[45\I4ES2;/LZ,>6FD7.E<!\
M0/$J:=9NB/AL>M=/KVL1Z98R,S`,!7S3XU\42:I?21AB5S6V'HN<KDUIV5D8
M.JW\FI7C2,Q/-5U&%J*([:5YN"*]I*RL>=*[8NUIG"+R2:]H^&7A82!)I4]^
M:\X\&Z*^IZDF4)7-?3?AS25TRQ10N#BN'%U;+E1TT*=W<UX8EAB5%Z"I*0T5
MY1WF!XHT9-4L'RH+`5\Q^+-(?3=3<!<+FOKIE#H5/<8KR'XD>%1)$]RJ<]>E
M=F%J\LK,YJ]._O(\*1L@"FRKGD4DBM;W+HPQ@T[S,BO86J//::>AV7@;Q-)I
M]]'$SD+D"OI31[^._L(Y%;)Q7QM%.UM.)5[&O;_AKXR\T)!*_MR:\_%T;^\C
MLH3:=CVDTHJ.*59HPZG@T^O+V.T**6B@`[5XK\3OO25[4>E>)_$]\-)73A?C
M,:_PGBC?Z]OK1/TJ,R?OV^M+/)Q7M'G-/F.O\#?\?\?UKZ<T?_D&Q?2OF#P+
M)G4(_K7T_HW.F1?2O*QOQ';AR]2TE%<)U"/]QOI7@WQ6_P!8]>\O]QOI7@?Q
M7?$CUU83XSGQ'PGDR5)C-5XY*E\RO:6QYS3N7;._DL&W(2*UU\:7:KCS&KFB
MP;K3<+Z5#IQEN5&31T__``FEW_ST;\Z/^$TN_P#GHWYUS&%HPOI2]E'L/G9T
M_P#PF=W_`,]&H_X32[_YZ-7,87THPOI1[*/8.=G3_P#":7?_`#T:@^-;L''F
M-7,87TII"[NE'LHC4V=K9Z_/?-AV)S6J5RF?6N2T7`<5UJ/D*OK7H8>*C'0^
M>S!MU`M[AK28.IQS7J?A+Q*DD2QR/7G?]D230[U4U4BN+C3)^,C%88BC#$*W
M4K"XBIAI*70^B4N(I%!5P<T_<OJ*\>TSQC(B*'?]:VU\;IM^^*\2>`JIV2/H
M89I1DKL]$:6-!EF`KE/$WB&.WMV2-QFN4U#QFSH0C_K7'7^JSWDA+,2#73AL
MNDY7F<N+S6/+RTQ-2OFO)V8G/-3Z#8->7:C;D9JC:6LEW,%53R:]3\(^'/LZ
MK*ZUZ.*K1H4[(\K"X>>(J79U&@6(L[-1C!Q6C=_\>K_2I54*,#I4-W_QZO\`
M2OFG)RE=GUJ@H4^5'B7B[_C^;ZUBZ9_Q_)]:V/%K?Z>WUK%TU\7R?6OJZ*_<
M'QE;^._4]U\-_P#(/7Z5IWD`GMF0CJ*R_#1SIZ?2MROEJSM49]AATG12/%_%
MVBO;3-(J\9KD(G,3[NA%>]:_HR:A;MA><5X[KFB2V$[84XS7O8#%1J0Y);GS
MF8X-TI\\=CJO"'B3R2L<C\5Z9;WL-Q$&5QS7SG%<R6[@ID$5T^E>*YX`%=S@
M>]98O+N9\\#;!9G[-<DSVW<I[BD,B#JP%><1>-T"#+_K5>[\:[E.UZ\U8&JW
M:QZG]I4;7N=UJVL0V=NQ#C.*\A\1ZX]_.RALBJNI^(;B[8C<<5CJ&FDP`237
ML83`*E[TSQ,;CY5WRQV%BC:9P@Y)->H>"=$*(KNM8/A?PR\\RR.IQUKUFPLT
MLX%11CBN?,<6K<D3HRO!-R]I(LHH1`H[44ZBO#/I#ROX@K?71DBA#8.1Q7D#
M>"M1FG,C1L<GTKZHFTZVN&W21AC3!I%B!_J%_*NJEB735D83I.3/F`^"+[_G
MDWY5$G@B_:X4&)L9]*^I?[)LO^>"T#2;('/D+GZ5H\;(A8:QYYX"\(?V>B22
M1X8>HKT\```#M38XDB7"*`*=7)4FYN[-X1459!12T5!85F:Y8+J%@\17)Q6G
M28SP::=G<35U9GS;XI\!W*WCO#&<$]A6%%X)ORO,3?E7U/+86TQS)$IJ,:19
M#_E@OY5V1QDDK'.\.F?+DG@>^*$>4WY5H^'_``[J>EWJ,$<#-?27]DV7_/!?
MRI/['L<Y\A<_2AXQM68EA[;%'PS)*VGJ)<YP.M;E110)`NV,8%29KC;N[G2M
M$%+24M(8AZ5Y/\0=$GOR_EJ3FO6*AELX)O\`6(&JZ<^1W(G'F5CY3_X0B_\`
M/)\INOI2S^"+\KQ$WY5]2?V18YSY"_E2G2+(]8%_*NOZ[(P^K]3Y]\'^$[RT
MO49XV`!]*^@]+C,5A&AZ@4L>F6D9RD*@U9"A1@=*YJM5U'=FU.'*.I**6LC0
M1_N'Z5XS\1_#]QJ,C&-"?I7LQJ"6RMY_]9&&^M:4ZC@[HB<.=6/E6/P1?_\`
M/)ORJ3_A"+[_`)Y-^5?4']D6/_/!?RI?[)LO^>"UU?79&'U8^7O^$)OO^>3?
ME1_PA-]_SR;\J^H?[)LO^>"T?V39?\\%H^NR#ZLCY>_X0F^_YY-^5'_"$WW_
M`#R;\J^H?[)LO^>"T?V39?\`/!:/KL@^K(^7O^$)OO\`GDWY4?\`"$WW_/)O
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M()0?E6I#IMM"!MC%14S1V]TNED^MY,Y'0/"$<`61U&17:PPI!&$48`IX4*,`
M8%%>75K2JN\CV:&'A15HBU#=+NMW`[BI:",C!K):,V:NK'C_`(FT*XN+QF12
M>:R=/\.72W:,4/!KVY[&WD.60&D73K93D1BO2AF,HPY3R)95&4^8HZ!`T%FJ
ML,'%:]-6-4&%&*=7G3ES2YCU:<.2/*+UXK#U?P_#J",=HS6W2TX3E!W0ITXU
M%:1X[J_@Z2%V,:'\JY>?1;R)B-AKZ%DMXI1\Z`UG7&@VLW(0?E7J4<TE%6D>
M17RB,M8'@1T^['\+4Y=,NV/W&KVUO"]N3G8/RJ2/PS;*1E!^5=#S6/1'(LGG
MW/';/P]=3.`R''TKM=$\%@E7D2N]@TBUAZ1C/TJ\D:1C"@"N2OF4YJR.[#Y5
M"#O(JV&GQ6405%&15RDS17F-MN[/6C%15D+11104%%%)F@!:*3-+0`4444`%
M%%%`!1110`4444`%%%%`!28I:*`"BC-%`!BBBB@`HHHH`****`$I:**`"BBB
M@`HHHH`****`"BBB@`HHI,T`+1110`4444`%&**,T`%%)FEH`**3-+0`48HH
MH`*#110`E+110`48HHH`,4444`%%%%`!1110`48HHH`3%+BBB@`HHHH`0T44
M4`+1110`4444`%%%%`!1110`4444`%%%%`!1110`E%%%`"T444`%%%%`!111
M0`4444`%%%%`!1110`4E%%`!1110`M)110`HHHHH`****`"DHHH`****`"EH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
